New Taipei City, Taiwan, November 19, 2026
Caliway Biopharmaceuticals Co., Ltd. has announced that its investigational injectable drug candidate CBL-514 has received authorization to proceed from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The regulatory clearance covers the company’s China clinical study, designated CBL-0102, which will evaluate the pharmacokinetics, safety and tolerability of CBL-514 in healthy Chinese participants. The authorization was granted ahead of the company’s anticipated timeline and represents an important milestone in its global clinical development strategy. Caliway expects to begin participant enrolment in December 2026, with the study scheduled for completion in the second quarter of 2027 and clinical data anticipated shortly thereafter. The programme is designed to generate information about potential ethnic differences in how the drug is processed and tolerated, supporting future clinical development and regulatory submissions in China and other Asian markets. CBL-514 is being developed as a novel injectable treatment for large-area localized subcutaneous fat reduction, with additional research exploring its potential in cellulite. The latest regulatory development expands the company’s clinical programme beyond its existing development activities in North America, Australia and Taiwan.
CBL-514 Uses a Novel Mechanism for Localized Fat Reduction
CBL-514 is a patented, investigational small-molecule injectable drug developed by Caliway. It is designed to selectively induce adipocyte apoptosis, a programmed cell-death process affecting fat cells, at the injection site. The objective is to reduce localized subcutaneous fat without causing necrosis or damaging surrounding tissues and cells. Unlike conventional body-contouring approaches that rely on surgical fat removal or energy-based technologies, CBL-514 is being investigated as a pharmacological approach to localized fat reduction. The company’s development programme is focused on applications including non-surgical subcutaneous fat reduction and moderate-to-severe cellulite. A separate formulation, CBL-514D, is also being developed for Dercum’s disease, a rare condition associated with painful fatty tissue deposits. Caliway reports that more than 544 participants have taken part in clinical trials involving CBL-514. The company also states that all primary and key secondary efficacy endpoints were met across 10 completed clinical trials with finalized statistical reports. These are company-reported findings, and individual trial results should be evaluated according to their study designs, participant populations and endpoints. The investigational candidate has not yet received marketing approval for these applications.
China Study to Assess Pharmacokinetics and Safety
The newly authorised CBL-0102 study is designed as a randomized, open-label, single-dose, parallel-group clinical investigation involving approximately 30 healthy Chinese participants at two clinical sites in China. Its primary objective is to assess ethnicity sensitivity by examining whether ethnic factors influence the pharmacokinetic profile, safety and tolerability of CBL-514 across different dose levels. Pharmacokinetic assessments help researchers understand how a medicine is absorbed, distributed, metabolised and eliminated by the body. Such information can be important when developing medicines for different populations, particularly when planning dose selection and subsequent clinical studies. The study is not designed to establish the drug’s fat-reduction efficacy in patients. Instead, the results are expected to provide clinical information to support the planning of future pivotal studies and potential regulatory submissions in China. Caliway also believes the data could be useful for development strategies in other Asian markets. The company expects the study to begin enrolling participants in December 2026 and anticipates clinical data in the second quarter of 2027. Successful completion would provide another regulatory and clinical milestone as the candidate progresses through its development programme.
China Expansion Strengthens Caliway’s Global Development Strategy
Caliway views China as an important market for aesthetic medicine and body-contouring treatments. The company cites projections that China’s body-contouring market could reach RMB 643 billion by 2040, reflecting increasing demand for aesthetic procedures and localized fat-reduction solutions. The CBL-0102 authorization provides an opportunity to generate population-specific clinical data that may support future development and commercial planning in the region. The company intends to use the findings to inform subsequent clinical stages and regulatory discussions, while continuing its programmes in other international markets. The China study also forms part of Caliway’s broader strategy to strengthen the global development and potential licensing opportunities for CBL-514. However, the regulatory authorization to conduct this study should not be confused with approval to market the medicine in China. CBL-514 remains investigational, and further clinical trials will be required to establish its efficacy and safety for localized fat reduction. The upcoming study will primarily contribute pharmacokinetic and safety information rather than confirm clinical benefits. Its results are expected to guide Caliway’s next development decisions and support the potential expansion of the programme across Asia.
Source: Caliway Biopharmaceuticals press release



